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PURPOSE. A critical event in the pathogenesis of diabetic reti-
nopathy is the inappropriate adherence of leukocytes to the
retinal capillaries. Advanced glycation end-products (AGEs) are
known to play a role in chronic inflammatory processes, and
the authors postulated that these adducts may play a role in
promoting pathogenic increases in proinflammatory pathways
within the retinal microvasculature.
METHODS. Retinal microvascular endothelial cells (RMECs)
were treated with glycoaldehyde-modified albumin (AGE-Alb)
or unmodified albumin (Alb). NFB DNA binding was mea-
sured by electromobility shift assay (EMSA) and quantified with
an ELISA. In addition, the effect of AGEs on leukocyte adhesion
to endothelial cell monolayers was investigated. Further stud-
ies were performed in an attempt to confirm that this was
AGE-induced adhesion by co-incubation of AGE-treated cells
with soluble receptor for AGE (sRAGE). Parallel in vivo studies
of nondiabetic mice assessed the effect of intraperitoneal de-
livery of AGE-Alb on ICAM-1 mRNA expression, NFB DNA-
binding activity, leukostasis, and blood–retinal barrier break-
down.
RESULTS. Treatment with AGE-Alb significantly enhanced the
DNA-binding activity of NFB (P  0.0045) in retinal endothe-
lial cells (RMECs) and increased the adhesion of leukocytes to
RMEC monolayers (P  0.04). The latter was significantly
reduced by co-incubation with sRAGE (P  0.01). Mice infused
with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1
mRNA when compared with control animals (P  0.001, n 
20) as early as 48 hours, and this response remained for 7 days
of treatment. Quantification of retinal NFB demonstrated a
threefold increase with AGE-Alb infusion in comparison to
control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P  0.001,
n  10 mice). AGE-Alb treatment of mice also caused a signif-
icant increase in leukostasis in the retina (AGE-Alb versus Alb,
6.89 vs. 2.53, n  12, P  0.05) and a statistically significant
increase in breakdown of the blood–retinal barrier (AGE Alb
versus Alb, 8.2 vs. 1.6 n  10, P  0.001).
CONCLUSIONS. AGEs caused upregulation of NFB in the retinal
microvascular endothelium and an AGE-specific increase in
leukocyte adhesion in vitro was also observed. In addition,
increased leukocyte adherence in vivo was demonstrated that
was accompanied by blood–retinal barrier dysfunction. These
findings add further evidence to the thinking that AGEs may
play an important role in the pathogenesis of diabetic
retinopathy. (Invest Ophthalmol Vis Sci. 2003;44:4457–4464)
DOI:10.1167/iovs.02-1063
The formation and accumulation of advanced glycation end-products (AGEs)1 is one of several pathogenic mecha-
nisms that may contribute to diabetic microvasculopathy. AGEs
can form on the amino groups of proteins, lipids, and DNA
through several complex pathways, including nonenzymatic
glycation by glucose and reaction with ascorbate, metabolic
intermediates, and reactive dicarbonyl intermediates. These
reactions modify the structure and function of proteins and
may lead to formation of complex cross-links.2 Metal-catalyzed
oxidative reactions also give rise to a group of AGEs, classified
as glycoxidation products (e.g., N-(carboxymethyl)lysine
[CML] or N-(carboxyethyl)lysine [CEL])3,4 that also accumu-
late on macromolecules with aging and at an increased rate in
diabetes.5
AGEs can induce a range of pathogenic effects in retinal
microvascular endothelium in vitro, many of which are medi-
ated through AGE-receptors.6–8 In in vivo systems, however,
the role of AGEs in diabetic retinopathy continues to remain
equivocal. AGEs are known to accumulate in the neural retina
and vascular cells of diabetic animals9,10 where they appear to
initiate pathophysiological changes in retinal microvascular
function.11 In addition, the AGE inhibitor, aminoguanidine, can
attenuate formation of retinopathic lesions in diabetic animal
models.12–16 A critical early event in the pathogenesis of dia-
betic retinopathy is leukocyte adhesion to the diabetic retinal
vasculature. The process is mediated in part by upregulation of
intercellular adhesion molecule (ICAM)-1 by the retinal micro-
vascular endothelium17 and contributes to blood–retinal bar-
rier breakdown and capillary nonperfusion.18 Recent data have
pointed to the role of leukocyte adhesion in the production of
retinal disease, and diabetic retinopathy is now a recognized
inflammatory disease. Significantly, the ICAM-1 and VCAM-1
genes are controlled by multiple binding sites for transcription
factors, including NF-B, which is closely linked to AGE-medi-
ated generation of oxidative stress.19–21
The role of AGEs in modulation of proinflammatory re-
sponses during the development of diabetic retinopathy re-
mains unknown. In the present study we investigated the
effect of the AGE-modified proteins on the expression of ad-
hesion molecule ICAM-1, transcription factor NFB and leuko-
cyte adhesion in vitro and in vivo.
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METHODS
Preparation of AGE-Modified Proteins
AGE-modification of bovine serum albumin (BSA) or mouse serum
albumin (MSA; fraction V; Sigma-Aldrich, Poole, UK) was performed
according to the protocols previously described by Nagai et al.22
Briefly, albumin (2 mg/mL) was incubated with 33 mM glycoaldehyde
at 37°C for 7 days in phosphate-buffered saline (PBS; pH 7.4). After
dialysis against PBS, endotoxin was removed using an endotoxin-
separation column (Pierce, Inc., Rockford, IL). Glycoaldehyde-modi-
fied albumin (AGE-Alb) and native albumin (Alb) were passed through
separate columns three times to ensure that all contaminating endo-
toxin had been removed. Aliquots were tested for endotoxin by an
independent company (Endosafe; Charles River Laboratories, Wilming-
ton, MA).
In addition, BSA which had been modified to yield CML specifically
was characterized. The CML-BSA was kindly prepared by Suzanne
Thorpe (University of South Carolina). Briefly, 10% and 35% modified
albumin was prepared by reacting different ratios of glyoxylic acid
(COOHCHO) with BSA in the presence of sodium cyanoborohydride.
Analysis of the CML and CEL content of AGE-Alb and native albumin
was performed by Suzanne Thorpe, using gas chromatography mass
spectrometry (GC-MS). The specificity and degree of modification of
the 10% and 35% modified BSA were quantified with GC-MS analysis as
well.
Lysine content of the samples was analyzed by cation exchange
chromatography, and the levels of CML and CEL were corrected for
lysine loss and expressed as moles CML or CEL per mole BSA.23
In Vitro Experiments
AGE Treatment of Endothelial Cells. HUVECs or bovine
retinal microvascular endothelial cells (RMECs, passages 2–4) were
isolated and cultured as described previously.24 RMEC monolayers
were cultured in phenol red–free DMEM containing 10% fetal calf
serum, to which AGE-Alb at various concentrations (150–400 g/mL)
was added. Control cells were grown in the presence of native albumin
at the same concentration for 1 to 24 hours.
Nuclear Extraction from AGE-Treated Cells and Mea-
surement of NFB by EMSA. Nuclear protein was extracted from
AGE-treated cells or control cells and assessed for NFB DNA binding
activity by electromobility shift assay (EMSA), as previously described
by Digman et al.25 Briefly, cells were washed with ice-cold PBS and
lysed in hypotonic buffer followed by centrifugation at 14,000 g for 10
minutes at 4°C. The pellet was resuspended in hypotonic buffer with
0.01% vol/vol Igepal and incubated for 10 minutes on ice followed by
centrifugation. The pellet was resuspended in nuclear lysis buffer for
15 minutes on ice and after centrifugation the supernatant containing
the nuclear extract was collected and stored at 70°C. A 32P-labeled
probe for NFB (5 AGTTGAGGGGACTTTCCCAGGC 3; Promega,
Madison, WI) was prepared and incubated with protein for 45 minutes
at 65°C. The radiolabeled mixture was separated on 40% bis-acrylamide
gels, and bands on the gels were visualized after developing overnight
at 80°C on autoradiograph film (Eastman Kodak, Rochester, NY).
Aliquots of nuclear protein were also assayed for p65 activity using
quantitative ELISA as described later.
In Vitro Adhesion of Isolated Leukocytes. Fresh heparin-
ized human blood from a healthy volunteer was collected, and the
peripheral blood mononuclear cells (MNCs) were isolated as previ-
ously described by Pertoft et al.26 The MNCs were used immediately
for the endothelial cell–leukocyte adhesion assay. An in vitro adhesion
assay was performed using human umbilical vein endothelial cells
(HUVECs) and MNCs treated for 4 hours with AGE-Alb (100 g/mL).
The MNCs were labeled with a lipophilic fluorescent probe (Cell
Tracker CM-DiI; Molecular Probes, Eugene, OR) before incubation on
endothelial cells. After they were washed twice, the DiI-labeled cells
(5  105 cells/mL) were added to the confluent monolayers of endo-
thelial cells for 30 minutes at 37°C. The nonadherent cells were
removed with prewarmed medium, and the fluorescent attached cells
were quantified with a 96-well microplate reader (Molecular Devices,
Sunnyvale, CA).
Preparation of Soluble RAGE. The soluble form of RAGE
(sRAGE) was prepared in a baculovirus expression system (6 His
Expression and Purification Kit; BD PharMingen, San Diego, CA) with
Sf9 insect cells. Serum-free medium containing sRAGE with 6 histi-
dine at the N-terminal was subjected to purification with Ni-NTA
agarose gel. The final product produced a single band of 40 kDa in
SDS-PAGE. Endotoxin content in the sample was measured by an
amebocyte lysate assay (Limulus, E-Toxate; Sigma-Aldrich) and found to
be below detectable level (0.02 ng/mL).
Effect of Co-incubation with sRAGE. An in vitro leukocyte
adhesion assay was performed exactly as just described. The effect of
co-incubation of sRAGE (1500 g/mL) with AGE-Alb (100 g/mL) on
leukocyte adhesion to endothelial cells was monitored. The same
concentration of nonimmunized mouse IgG (Sigma-Aldrich) was used
as a control protein to test for the effect of a generic protein.
In Vivo Experiments
Animals and Anesthesia. Twenty-gram male C57/BL6 mice
were obtained from Charles River Laboratories. All animal experiments
were approved by the Massachusetts Eye and Ear Infirmary Animal
Care and Use Committee and conformed to the Association for Re-
search in Vision and Ophthalmology guidelines. Before all experimen-
tal manipulations, the mice were anesthetized with an intramuscular
injection of 25 mg/kg of ketamine hydrochloride (Parke-Davis, Morris
Plains, NJ) and 4 mg/kg of xylazine hydrochloride (Phoenix Pharma-
ceuticals, St. Joseph, MO).
AGE Treatment of Mice. AGE-treated mice received 10 mg/kg
AGE-Alb or native albumin every day for seven consecutive days by
interperitoneal injection. All proteins were passed through an endo-
toxin-removing column (Pierce, Inc.) and the absence of contaminat-
ing endotoxin was confirmed by an independent company (Endosafe;
Charles River Laboratories). Endotoxin free PBS (Sigma-Aldrich) was
used for any necessary dilution of AGE samples before injection.
Real-Time PCR Quantification of ICAM-1 mRNA Ex-
pression in Retina. Mouse Retinal RNA Extraction. Groups of
mice were killed as just described, the eyes enucleated, and the retina
dissected away from the posterior eye cup and placed in a stabilization
reagent (RNA-Later; Ambion, Inc. Austin, TX) at 4°C. Total retinal RNA
was isolated with extraction reagent (TRIzol Reagent; Invitrogen-
Gibco, Paisley, Scotland, UK) according to manufacturers’ instructions.
Briefly, one retina was mixed with 1 mL of extraction reagent at room
temperature. Retinas were homogenized using a plastic pestle (Geno-
Technology Inc., Maplewood, MO) attached to a handheld drill for
three 15-second bursts, and the lysate was allowed to sit at room
temperature for 10 minutes to allow nucleoprotein dissociation. The
lysate was loaded into a shredder (Qiashredder; Qiagen Inc., Valencia,
CA) to aid homogenization, followed by centrifugation at 12,000g for
5 minutes. The supernatant was removed to an RNase free tube
(Eppendorf, Fremont, CA), and 200 L chloroform was added and
vortexed to mix. After incubation at room temperature for 10 minutes,
phase separation was performed by centrifugation at 12,000g for 15
minutes at 4°C. The upper aqueous phase containing the RNA was
carefully removed to an RNase-free tube and the RNA precipitated in
500 L isopropanol for 15 minutes followed by centrifugation at
12,000g at 4°C. The RNA pellet was washed twice with 75% ethanol
and resuspended in 25 L of diethyl pyrocarbonate (DEPC) water. RNA
integrity and quality was confirmed by analysis by 260:280-nm ratio
and visualization of ribosomal 28S and 18S RNA bands on a 0.5%
agarose gel. cDNA was synthesized from 2 g total retinal RNA using
a reverse transcriptase cDNA synthesis kit (Superscript II; Invitrogen-
Gibco) according to the manufacturer’s instructions on an automated
system (GeneAmp PCR System 9700; Applied Biosystems, Foster City,
CA). cDNA was diluted fivefold before PCR amplification.
Real-Time PCR. Real-time PCR analysis was performed using
the fluorogenic probe-based 5 exonuclease assay (Taqman, Applied
Biosystems) on an automated sequence detection system (model 7700;
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Applied Biosystems) according to the manufacturers’ instructions. Re-
actions were performed in a 50-L volume of a master mix (Taqman
Universal PCR Master Mix; Applied Biosystems) with the following sets
of primers and probes for detection of ICAM-1 and RPL32: mRPL32
probe CCTCTGGTGAAGCCCAAGATCGTCA, forward primer TCATG-
GCTGCCCTCCG, reverse primer TGACTGGTGCCTGATGAACTTCT;
mICAM-1 probe TCCGTGCAGGTGAACTGTTCTTCCTCA, forward
primer AGGTATCCATCCATCCCAGAGA, reverse primer GAGCT-
CATCTTTCAGCCACTGA.
A quantitative RT-PCR methodology (Taqman; Applied Biosystems)
was used to measure the retinal ICAM-1 gene copy number, which was
normalized to the ribosomal protein L32 mRNA copy number.27 Linear
standard curves were created during each amplification using 102 to
108 copies of ICAM-1 or RPL32 plasmids (gifts from Iain Campbell,
Scripps Research Institute, La Jolla, CA). Control amplification (no
probe and no template) samples were included in each reaction to set
baseline and threshold levels.
Measurement of Activation of Retinal NFB
Preparation of Nuclear Extracts. Eyes were enucleated after
seven daily intraperitoneal injections of 10 mg/kg AGE (GA-Alb) or
nonglycated albumin (Alb, 10 mg/kg), and the retinas were removed
and snap frozen. Nuclear extraction of retinal protein was performed
as described previously. Briefly, retinas were snap frozen and stored at
70°C. Pooled retinas were homogenized with a mechanical homog-
enizer in five pellet volumes of Buffer A (20 mM Tris [pH 7.6], 10 mM
KCl, 0.2 mM EDTA, 20% [by vol] glycerol, 1.5 mM MgCl2, 2 mM
dithiothreitol [DTT]), 1 mM Na3VO4 and protease inhibitors; Com-
plete; Roche Diagnostics, Mannheim, Germany). Nuclei were pelleted
(2500g, 10 minutes) and resuspended in two pellet volumes of Buffer
B (identical with Buffer A except that KCl was increased to 0.42 M).
Nuclei debris was removed by centrifugation (15,000g, 20 minutes),
and the supernatant was dialyzed against one change of buffer Z (20
mM Tris-HCl [pH 7.8], 0.1 M KCl, 0.2 mM EDTA, and 20% glycerol) for
at least 3 hours at 4°C in dialysis cassettes (Dialyze Z; Pierce, Inc.).
Protein concentration was measured with the bicinchoninic acid
(BCA) assay.
Quantification of NF-B Activation. NF-B activation was
analyzed with a transcription factor assay kit (trans-AM NF-B/p65;
Active Motif North America, Carlsbad, CA) according to the manufac-
turer’s instructions. Briefly, 2 mg of the retinal nuclear extracts or
bovine retinal endothelial cell extracts (prepared as listed earlier) were
incubated with an oligonucleotide containing the NF-B consensus site
(5-GGGACTTTCC-3) bound to a 96-well plate. After extensive
washes, the NF-B complexes bound to the oligonucleotide were
incubated with an antibody directed against the NF-B p65 subunit at
a dilution 1:1000. After washes, the plates were subsequently incu-
bated with a secondary antibody conjugated to horseradish peroxidase
(1:1000), and the peroxidase reaction was quantified at 450 nm with a
reference wavelength of 655 nm. Results are expressed in absorbance
units corrected for interference at the reference wavelength.
Evan Blue Leakage Assay for Quantification of
Inner Blood–Retinal Barrier
Mice were treated with AGEs as described earlier and processed for
Evans blue leakage assay for detection of breakdown of the inner
blood–retinal barrier, exactly as described previously by Xu et al.28 and
Qaum et al.29 Evans blue dye was injected into the bloodstream of mice
treated with AGE-Alb or native albumin through the tail vein and
allowed to circulate and bind to plasma albumin.
Briefly, animals were anesthetized, and Evans blue was injected
through the tail vein over 10 seconds at a dosage of 45 mg/kg.
Immediately after Evans blue infusion, the mice turned visibly blue,
confirming their uptake and distribution of the dye. After the dye had
circulated for 60 minutes, the chest cavity was opened, and the mice
were perfused for 2 minutes through the left ventricle at 37°C with
0.05 M (pH 3.5) citrate-buffered paraformaldehyde (1% wt/vol; Sigma-
Aldrich). The perfusion was at a physiological pressure of 120 mm Hg.
Immediately after perfusion, both eyes were enucleated and bisected
at the equator. The retinas were carefully dissected and thoroughly
dried in a concentrator (Speed-Vac; Thermo Savant, St. Paul, MN) for 5
hours. Evans blue was extracted by incubating each retina in 65 L
formamide (Sigma-Aldrich) for 18 hours at 70°C. The supernatant was
filtered through tubes (Ultrafree-MC; 30,000 NMWL; Millipore, Bed-
ford, MA) at 3000g, and the filtrate was used for triplicate spectropho-
tometric measurements (Du-640; Beckman Instruments, Fullerton,
CA). Each measurement occurred over a 5-second interval, and all sets
of measurements were preceded by known standards. The back-
ground-subtracted absorbance was determined by measuring each
sample at both 620 nm, the absorbance maximum for Evans blue in
formamide, and 740 nm, the absorbance minimum. The concentration
of dye in the extracts was calculated from a standard curve of Evans
blue in formamide and normalized for retina dry weight. Blood–retinal
barrier breakdown was calculated with the following equation, with
results expressed in microliters plasma  grams retina dry weight 
hours
Evans blue (g)/retina dry weight (g)
time-averaged Evans blue concentration
(g/plasma L)/circulation time (hr)
.
Results were expressed as the percentage of native Alb control levels.
Quantification of Retinal Leukostasis
With mice under deep anesthesia, the chest cavity was carefully
opened, and a 14-gauge perfusion cannula was introduced into the left
ventricle into the ascending aorta. Drainage was achieved by cutting
the edge of the right atrium. Animals were perfused with PBS (250
mL/kg body weight, 4 mL) at physiologic pressure (flow rate 0.2
mL/sec) to remove erythrocytes and nonadherent leukocytes from the
vasculature. This was followed by perfusion with FITC-conjugated
concanavalin A lectin (20 g/mL in PBS [pH 7.4], 5 mg/kg, 4 mL) to
label the adherent leukocytes and the vascular endothelial cells. Resid-
ual unbound lectin was removed by a repeat PBS perfusion. Eyes were
enucleated and the retinas carefully removed and flatmounted, and
leukocyte adherence to vessel walls was monitored with a fluores-
cence microscope (Axiovert with FITC filter; Carl Zeiss Meditec,
Oberkochen, Germany; with Improvision Openlab software; Coventry,
UK). The total number of leukocytes adhering in the retinal vasculature
was counted and compared between AGE-Alb–treated mice and Alb-
treated mice.
Statistical Analysis
All results were expressed as the mean  SEM. Paired groups of two
with equal variance were compared using a two-sample t-test. Differ-
ences were deemed statistically significant when P  0.05.
RESULTS
Analysis of the CML and CEL Content of AGE-Alb
and Native Alb
The CML and CEL content of AGE-Alb and native unmodified
Alb were analyzed by GC-MS. The lysine content of the samples
was analyzed by cation-exchange chromatography and values
were expressed as millimoles CML or CEL per mole lysine
(Table 1).
The AGE-Alb used in this study contained 23.85 mmol
CML/mol lysine compared with a control value of 0.286 mmol
CML/mol lysine. These results demonstrate a significant mod-
ification of the protein by the reactive intermediate glycoalde-
hyde, resulting in the generation of at least one major quanti-
fiable end product, namely CML. The low level of CEL formed
served as a control for the reaction, and the increase noted in
AGE-Alb compared with that of native albumin was not statis-
tically significant. In addition, BSA modified to specifically yield
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CML was prepared and characterized. The specificity and
degree of modification was quantified by GC-MS analysis
(Table 2).
The present study showed that unmodified, native albumin
contains 0.146 mmol/mol lysine CML, whereas mildly (10%)
and highly (35%) modified albumin contains 32.6 and 88.5
mmol/mol lysine CML, respectively. The fact that the CEL was
not increased demonstrates the specificity of the reaction for
CML formation.
In Vitro Experiments
Activation of NFB by AGE-Alb. As determined by EMSA,
AGE-Alb caused a marked increase in NFB DNA binding when
compared with native, control albumin (Fig. 1A, AGE-Alb ver-
sus Alb, lane 3 versus lane 4). Quantification of p65 nuclear
protein by ELISA revealed a statistically significant increase in
the amount of p65 protein in the nuclei of AGE-Alb–treated
RMECs compared with Alb-treated control cells (Fig. 1B, AGE-
Alb versus Alb, optical density [OD] 2.3 vs. 2.0, n  3, P 
0.0045).
Increased Leukocyte Adhesion to Endothelial Cells
Treated with AGE-Alb. An in vitro cell adhesion assay was
performed on endothelial cells treated with AGE-Alb or
native Alb (100 g/mL for 4 hours). Isolated leukocytes
consistently displayed increased adhesion to endothelial cell
monolayers treated with AGE-Alb. Adherence levels were
similar to the adhesion seen with the positive control TNF.
Quantification of the number of leukocytes adhering to
AGE-treated endothelial cells (AGE-Alb) revealed a statisti-
cally significant increase when compared with the control
(Alb; Fig. 2). Results represent the average of 12 experi-
ments  SEM (AGE-Alb–treated versus Alb control, 202% 
21% vs. 100%  10%, P  0.01).
Effect of Co-incubation of sRAGE on AGE-Induced Leu-
kocyte Adhesion. An in vitro cell adhesion assay was per-
formed on endothelial cells treated with co-incubation of
sRAGEAGE-Alb or sRAGEnative Alb for 4 hours. Treatment
of cells using co-incubation of AGE-Alb with sRAGE (1500
g/mL) caused a significant reduction in the amount of AGE-
induced leukocyte adhesion to endothelial cell monolayers
(Fig. 2). Control experiments performed using the same con-
centration of nonimmunized mouse IgG (Sigma-Aldrich) to test
for the effect of co-incubation with a generic protein showed
no effect on AGE-induced adhesion (results not shown). Re-
sults represent the average of 12 experiments  SEM (AGE-
AlbsRAGE vs. AGE-Alb, 114%  13% vs. 202%  21%, P 
0.01).
In Vivo Experiments
To investigate the effect of AGEs on retinal vascular cells,
further experiments were performed in vivo by treating mice
with murine AGE-Alb or the Alb control every day for seven
consecutive days.
Effect of AGE-Alb on Retinal ICAM-1 mRNA Copy Num-
ber. A statistically significant increase was detected in retinal
ICAM-1 mRNA expression using a quantitative real time PCR
analysis. An almost twofold increase was noted in AGE-treated
retinas when compared with native Alb control retinas as early
as 48 hours after the first infusion. The increase was still
evident 7 days later (1.8-fold increase from control, P  0.001,
n  20, Fig. 3A). In addition, immunohistochemical analysis of
TABLE 1. Analysis of the CML and CEL Content of AGE-Alb and






Control albumin (Alb) 0.286 0.09
Glycoaldehyde-modified
albumin (AGE-Alb) 23.85 1.05
The AGE-Alb used in the study contained 23.85 mmol CML/mol
lysine compared with a control value of 0.286 mmol CML/mol lysine.
These results demonstrate a significant modification of the protein by
the reactive intermediate glycoaldehyde, resulting in the generation of
at least one major quantifiable end product, CML.







Control BSA 0.146 0.109
10% CML-BSA 32.6 0.091
35% CML-BSA 88.5 0.101
Unmodified/native albumin contained 0.146 mmol/mol lysine
CML while mildly (10%) and highly (35%) modified albumin contained
32.6 and 88.5 mmol/mol lysine CML, respectively. The fact that the
CEL was not increased demonstrated the specificity of the reaction for
CML formation.
FIGURE 1. (A) EMSA for detection of NFB DNA-binding proteins.
Retinal endothelial cells were treated with (lane 1) TNF, (lane 2)
hydrogen peroxide, (lane 3) AGE-Alb (150 g/mL), (lane 4) Alb
(150 g/mL), and (lane 5) AGE-BSA for 2 hours. Nuclear extraction
was performed followed by EMSA for detection of DNA binding
NFB proteins. In AGE-Alb–treated endothelial cells, increased
NFB DNA binding was noted (lane 3). No binding was noted in
control cells treated with native Alb (lane 4). (B) Quantification of
nuclear NFB in AGE-Alb–treated RMECs. NFB p65 protein was
quantified in nuclear extracts from RMECs treated for 2 hours with
AGE-Alb of native Alb (150 g/mL) using an ELISA. A statistically
significant increase in p65 was noted in those cells treated with
AGE-Alb compared with those treated with native Alb. Results
represent the average of three experiments  SEM (AGE-Alb versus
Alb OD, 2.3 vs. 2.0, P  0.0045).
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retinas from mice infused with AGE (10 mg/kg, 7 days) dem-
onstrated increased ICAM-1 protein expression in the retinal
vessels (Fig. 3C) when compared with Alb-infused control
mice (Fig. 3B).
Effect of AGE-Alb on Retinal NFB Expression. When
activation of retinal NFB was analyzed, a significant increase
in DNA binding NFB protein was detected in retinas of mice
treated with AGE-Alb compared with those treated with native
albumin (AGE-Alb versus Alb, 0.23 vs. 0.076, P  0.0001, n 
10, Fig. 4).
In Vivo Leukostasis Assay. An in vivo staining method
was used to determine whether more leukocytes adhered to
the retinal vasculature of the AGE-treated animals. In compar-
ison to control mice, AGE-Alb–infused animals showed a sta-
tistically significant increase in the number of leukocytes visi-
ble in the retinal capillary bed after removal of nonadherent
cells by perfusion.
A direct quantification of the number of leukocytes was
performed in all retinas and results represent the average 
SEM (Fig. 5, AGE-Alb versus Alb, 6.89  0.58 vs. 2.53  0.31 n
 12, P  0.05). The micrographs are representative of sta-
tionary leukocytes counted in the retinal vasculature of AGE-
Alb–treated mice.
AGE-Alb and Inner Blood–Retinal Barrier Breakdown.
Mice treated with AGE-Alb demonstrated a fivefold increase in
leakage of Evans blue dye, demonstrating a breakdown of the
blood–retinal barrier (AGE-Alb versus control Alb, 8.2 L vs.
1.6 L plasma  grams retina dry weight  hours, P  0.001,
Fig. 6).
FIGURE 2. In vitro leukocyte cell adhesion assay. Quantification of
the number of adhering leukocytes. A statistically significant in-
crease was found in the number of leukocytes adhering to AGE-Alb–
treated cells (100 g/mL for 4 hours) compared with the number
that adhered to control cells treated with native albumin. Results
represent the average of 12 experiments  SEM (AGE-Alb treated
versus Alb control, 202%  21% vs. 100%  10%, P  0.01). Effect
of co-incubation of sRAGE on AGE induced leukocyte adhesion.
Treatment of cell with co-incubation of AGE-Alb with sRAGE (1500
g/mL for 4 hours) caused a significant reduction in the amount of
AGE-induced leukocyte adhesion to endothelial cell monolayers.
Control experiments performed using the same concentration of
nonimmunized mouse IgG (Sigma-Aldrich) to test for the effect of
co-incubation with a generic protein showed no effect on AGE-
induced adhesion (results not shown). Results represent the aver-
age of 12 experiments  SEM (AGE-AlbsRAGE versus AGE-Alb,
114%  13% vs. 202%  21%, P  0.01).
FIGURE 3. (A) Effect of AGE-Alb infusion on mouse retinal ICAM-1
mRNA expression. A statistically significant increase in retinal ICAM-1
mRNA expression was detected. An almost twofold increase was noted
in AGE-Alb–treated mice when compared with Alb control retinas as
early as 48 hours after the first infusion, which remained after 7 days.
Results represent the average of 20 experiments  SEM (1.805-fold
increase over control, P  0.001). (B, C) Immunohistochemical anal-
ysis of ICAM-1 protein expression on retinas from AGE-infused mice.
Mice received native albumin (B) or glycated albumin (C) intraperito-
neally (IP) every day for 10 days (10 mg/kg). Retinas were removed,
flatmounted, and stained for ICAM-1. Increased intensity and more
frequent staining were observed in those retinas removed from AGE-
Alb infused mice (B).
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DISCUSSION
The inappropriate adherence of leukocytes to the retinal cap-
illary endothelium has been established as an important patho-
genic event in animal models of diabetic retinopathy and plays
a significant role in the breakdown of the blood–retinal barrier
and retinal capillary occlusion.17 Leukostasis is a manifestation
of chronic inflammation in the retinal microvasculature and is
dependent on a complex interplay between distinct cell types.
The phenomenon appears to be modulated by diabetes-related
activation of circulating leukocytes coupled with the marked
upregulation of adhesion molecules such as ICAM-1 by the
microvascular endothelium.18,30 In the present study, we
adopted several investigative approaches to establish a role for
advanced glycation in retinal leukostasis. It was important to
consider activation of the ICAM-1 gene, which is controlled by
transcription factors (such as NF-B) that are closely linked to
AGE-mediated generation of oxidative stress.31 We hypothe-
sized that the adhesion of leukocytes, both in vitro and in vivo,
was a functional representation of AGE-mediated dysfunction
of the retinal vascular endothelium.
AGEs are known to circulate at high levels in diabetic
persons,32 and the model adopted in the present study helps to
dissect some of the complexities of the diabetic milieu. Previ-
ous studies have demonstrated that AGEs infused into normo-
glycemic animals accumulate in the retinal microvasculature
and can induce diabetic-like retinal vascular lesions, such as
loss of capillaries, blood–retinal barrier dysfunction, and VEGF
upregulation.11,33 In the kidney, long-term AGE infusion can
induce diabetes-like glomerulosclerosis in nondiabetic ani-
mals.34,35 Such approaches have limitations, although they can
present a model in which acute effects of circulating AGEs can
be studied within an in vivo system.
Although the AGE-albumin used in the present study repre-
sents a model AGE, glycoaldehyde modification is physiologi-
cally relevant, because this aldehyde is known to occur at
elevated levels in diabetic individuals and serves as an impor-
tant intermediate for AGE formation in vivo.36 Furthermore,
albumin modified by glycoaldehyde has been shown to act as
a functional ligand for the class-A macrophage scavenger re-
ceptor (MSR-A) with the likelihood of interacting with other
known AGE-receptors. In the present study, we have shown
that glycoaldehyde modification of albumin can lead to appre-
ciable levels of CML, and this compares well with a report by
Nagai et al.22 CML itself can lead to oxidative stress in endo-
thelial cells,37 and it has been suggested that this AGE can
directly stimulate the receptor for AGE (RAGE) thus activating
key cell-signaling pathways, such as NF-B, and modulating
gene expression.38,39 The involvement of RAGE signaling path-
ways in retinal leukostasis remains an important area for study.
Accumulation of AGEs, both within vessel walls and as
complex modifications of serum proteins, has been shown to
induce proinflammatory responses.33,40 These adducts can ac-
tivate leukocytes41,42 and promote upregulation of the adhe-
sion molecules VCAM-1 and ICAM-1 on the surface of macro-
vascular endothelial cells, phenomena that are central to the
role of AGEs in atherogenesis.33,43,44 Despite their increasingly
recognized role in macrovasculopathy, AGEs have received
little attention in diabetes-related inflammation in the retina.
The current investigation has demonstrated that advanced gly-
FIGURE 5. Effect of AGE-Alb infusion on mouse retinal leukostasis.
Mice were injected (IP) with AGE-Alb (10 mg/kg) or native Alb every
day for seven consecutive days. The number of leukocytes per retina
was counted after perfusion and increased leukostasis was noted in the
retinas of treated mice compared with Alb-treated control retinas. Data
represent the average  SEM of at least 12 experiments (AGE-Alb
versus Alb, 6.89  0.58 vs. 2.53  0.31, P  0.05). Micrographs are
representative of stationary leukocytes counted in the retinal vascula-
ture of AGE-Alb–treated mice.
FIGURE 4. Effect of AGE-Alb infusion on mouse retinal NFB. Mice
were injected (IP) with AGE-Alb (10 mg/kg) or native Alb every day for
seven consecutive days. Eyes were enucleated and retinas removed for
nuclear extraction followed by measurement of NFB. There was a
statistically significant increase in the amount of retinal NFB DNA
binding proteins noted in mice treated with AGE compared with those
infused with native Alb (AGE-Alb versus Alb, 0.23 vs. 0.076, P 
0.0001, n  10 mice).
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cation may play a significant role in retinal microvascular oc-
clusion by promoting endothelial cell responses that enhance
leukocyte adhesion to capillaries.
The ability of AGE-Alb to induce substantial activation of
ICAM-1 in the retinal microvascular endothelium, possibly
through increased transcription of NFB, is fresh evidence that
these adducts may play a hitherto unrecognized role in retinal
leukostasis. It has been demonstrated previously that ICAM-1
mRNA or protein levels need not be upregulated much beyond
1.5-fold to initiate marked adherence of leukocytes to the
retinal capillaries.18 In the present study, a small, yet signifi-
cant, elevation in retinal ICAM-1 and NFB activation occurred
very soon after AGE-Alb infusion (48 hours), and levels were
maintained at a consistently high level throughout the period
of treatment. Retinal leukostasis and blood–retinal barrier dys-
function occurred after the infusion of AGE into normal mice,
and these phenomena may be closely related to the aforemen-
tioned endothelial effects.
Blood–retinal barrier dysfunction is an established lesion of
diabetic retinopathy. The basis of abnormal retinal microvas-
cular leakage remains equivocal, although it has been shown
that VEGF plays a key vasopermeability role29,45 probably mod-
ulated through ICAM-1 and leukocyte adherence to the endo-
thelium.46 The current investigation has confirmed previous
reports that infused AGEs can lead to blood–retinal barrier
breakdown in vivo, and it is significant that this seems to
correlate spatially with ICAM-1 upregulation and leukostasis.
Effective neutralization of ICAM-1 can prevent blood–retinal
barrier breakdown in diabetic animals.18 Further research is
needed to establish whether AGE-mediated blood–retinal bar-
rier dysfunction is modulated by blockage of ICAM-1.
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